Amyloid Beta Kinetics and Enhancing the Diagnostic and Prognostic Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease

2017

The pathological process of Alzheimer’s disease begins decades before cognitive decline. It has become apparent that for disease-modifying therapies to be effective, early intervention is required. In order to screen those at risk, improved biomarkers of AD pathology are urgently needed to identify individuals early, while damage is not too severe and is potentially reversible. We are using the most advanced technology to identify a new generation of biomarkers.

Biomarkers/Diagnostics/Studies of Risk & Resilience Foundational Norelle Wildburger, Ph.D. Randall J. Bateman

Related Content:

Midlife Autoantibody Profiles and the Risk of Late-Onset Alzheimer’s Disease in Women Yu Chen 2024-10-31 Bioinformatics Platform for Modeling Alzheimer’s Progression (MAP-AD Platform) Ali Ezzati 2024-09-16 Understanding Human Brain Resilience to Alzheimer’s Pathology Teresa Gomez-Isla 2024-08-19 Utility of Blood-Based Markers for Predicting Amyloid-Related Imaging Abnormalities and Their Course in Mild Cognitive Impairment and Alzheimer’s Disease Subjects Undergoing Routine Clinical Treatment with Amyloid-Directed Antibodies P. Murali Doraiswamy 2024-01-12 Characterization of the Longitudinal Trajectories of the Synaptic Blood Marker Beta-Synuclein during Alzheimer’s Disease Pathogenesis and Improvement of the Measurement Procedure Patrick Oeckl Markus Otto 2023-09-19 Precision Medicine Prediction Model for Alzheimer’s Disease Using Cooperative Learning Approaches for Multi-Omic Data Christoph Lange 2023-05-02 Adding Genomics and Methylomics to Personalized Disease Prediction for Alzheimer’s Disease (EPIC4AD) Lars Bertram Christina M. Lill 2023-02-28 Identification and Validation of Plasma-Based Lipid Biomarkers for Early Alzheimer’s Disease in the Unique, Primarily Hispanic, South Texas Population Xianlin Han Bernard Fongang Juan Pablo Palavicini Tiffany F. Kautz 2023-02-23